drugset / Trial / NCT04601610
KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma
Phase 1/2
Terminated
6 enrolled
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Sunshine Lake Pharma Co., Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is an open, multi-center clinical trial, the purpose is to study the safety and preliminary efficacy of KN046 combined with Ningatinib in subjects with advanced hepatocellular carcinoma.
Timeline
- Start
- 2021-06-07
- Primary completion
- 2022-05-30
- Completion
- 2022-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT053PTSA | Unknown | 10 mg | — |
| Subject | CT053PTSA | Unknown | 20 mg | — |
| Subject | CT053PTSA | Unknown | 30 mg | — |
| Subject | CT053PTSA | Unknown | 40 mg | — |
| Subject | ERFONRILIMAB | Monoclonal antibody | 5 mg/kg | — |